Compare

United Therapeutics Corp vs BioMarin Pharmaceutical Inc vs Amneal Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	United Therapeutics Corp UTHR	BioMarin Pharmaceutical Inc BMRN	Amneal Pharmaceuticals, Inc. AMRX	Alnylam Pharmaceuticals, Inc. ALNY
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	$3.18B	$3.22B	$3.02B	$3.71B
Revenue growth (YoY)	+10.6%	+12.9%	+8.0%	+65.2%
Gross margin	87.9% (computed)	77.7% (computed)	36.9%	81.8% (computed)
Operating margin	46.9%	12.7%	13.1%	13.5%
Net margin	41.9%	10.8%	2.4%	8.4%
Net income	$1.33B	$348.90M	$72.06M	$313.75M
EPS (Diluted)	$27.86	$1.80	$0.22	$2.33
Operating cash flow	$1.56B	$827.99M	$339.99M	$524.08M
Free cash flow	$1.04B	$724.96M	$269.93M	$465.38M
Cash & equivalents	$1.56B	$1.31B	$282.03M	$1.66B
Total assets	$7.88B	$7.59B	$3.68B	$4.97B
Total liabilities	$783.80M	$1.51B	n/a	$4.18B
Shareholders' equity	$7.10B	$6.09B	-$70.79M	$789.18M
Return on year-end equity	18.8%	5.7%	n/a	39.8%
Shares outstanding	43.64M	192.30M	n/a	132.38M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	United Therapeutics Corp	BioMarin Pharmaceutical Inc	Amneal Pharmaceuticals, Inc.	Alnylam Pharmaceuticals, Inc.
Latest	$3.18B Ended 2025-12-31	$3.22B Ended 2025-12-31	$3.02B Ended 2025-12-31	$3.71B Ended 2025-12-31
1 year earlier	$2.88B Ended 2024-12-31	$2.85B Ended 2024-12-31	$2.79B Ended 2024-12-31	$2.25B Ended 2024-12-31
2 years earlier	$2.33B Ended 2023-12-31	$2.42B Ended 2023-12-31	$2.39B Ended 2023-12-31	$1.83B Ended 2023-12-31
3 years earlier	$1.94B Ended 2022-12-31	$2.10B Ended 2022-12-31	$2.21B Ended 2022-12-31	$1.04B Ended 2022-12-31
4 years earlier	$1.69B Ended 2021-12-31	$1.85B Ended 2021-12-31	$2.09B Ended 2021-12-31	$844.29M Ended 2021-12-31